Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.21.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Revenues $ 0 $ 0
Operating Expenses:    
Research and development 1,640,000 324,000
Selling, general and administrative (including $14,296,000 of stock compensation to officers and directors in 2021) 27,362,000 746,000
Loss from operations 29,002,000 1,070,000
Other Income (Expense):    
Change in fair value of derivative liability (21,000) 0
Interest expense 696,000 638,000
Total other expense, net 675,000 638,000
Net loss $ (29,677,000) $ (1,708,000)
Net loss per common share - basic and diluted $ (1.83) $ (0.41)
Weighted average common shares outstanding - basic and diluted 16,239,938 4,122,178